Psychopharmacologic Drugs : Antipsychotics
OSERO8 “Seroquel XR tablet” 200 mg/tab
OSERO9 “Seroquel XR tablet” 50 mg/tab
OSERO2 “Seroquel FC tablet” 100 mg/tab
OUTAP1 “Utapine FC tablet” 100 mg/tab
適應症：
OSERO2, OUTAP1：精神分裂症，雙極性疾患之躁症發作。
OSERO8, OSER09：治療精神分裂症、雙極性疾患之鬱症發作、躁症發作及混合性發作。對於抗鬱劑單一藥物治療效果不佳的重鬱症(MDD)病人，可作為重鬱症發作的附加治療。開始治療之前，臨床醫師應該考慮seroquel XR的安全性。
Usual dose:
Schizophrenia: initial, 25 mg bid, may increase dosage by 25-50 mg 2-3 times/day on the 2nd and 3rd day, as tolerated, to a target dose range of 300-400 mg/day by the 4th day, given in 2-3 divided doses; maintenance, at intervals of > 2 days in dose adjustments of 25-50 mg bid; effective dosage 150-750 mg/day divided 2-3 doses, max. 800 mg/day.
Manic episodes: initial, 50 mg bid, may increase dosage by increments up to 50 mg bid on the 2nd and 3rd day, to a target dose 400 mg/day by the 4th day given in 2 divided doses; maintenance, dosage adjustments in increments of < 200 mg/day up to 800 mg/day by day 6; effective dosage 400-800 mg/day, max. 800 mg/day.
Dose adjustment:
Geriatirc, hepatic impairment: initial, 25 mg/day, increase in steps of 25-50 mg to an effective dose.
Adverse effect:
Common: orthostatic hypotension, tachycardia, serum cholesterol raised, serum triglycerides raised, weight gain, abdominal pain, constipation, increased appetite, indigestion, vomiting, xerostomia, increased liver enzymes, backache, asthenia, dizziness, extrapyramidal disease, headache, insomnia, lethargy, sedated, somnolence, tremor, agitation, nasal congestion, pharyngitis, fatigue, pain.
Serious: syncope, agranulocytosis, leukopenia, neutropenia, neuroleptic malignant syndrome, seizure, tardive dyskinesia, suicidal thoughts, priapism.
健保使用規範：
1.需合乎衛生主管機關許可之適應症範圍，並需符合下列條件 (1)開始使用「第二代抗精神病藥品」時需於病歷記載：醫療理由或診斷，以及臨床整體評估表(CGI)之分數；(2)經規則使用六至八週後，需整體評估其療效，並於病歷記載：臨床整體評估表之分數；(3)日劑量超過時600 mg/day，須於病歷記載理由。